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Introduction
Adrenocortical carcinoma (ACC) is a rare aggressive malignancy with an annual incidence of 2 per million worldwide and an estimated 5-year survival rate of 16-44%.
1,2 Surgical resection is the treatment choice in localized disease and is frequently combined with adjuvant mitotane to increase the chance for cure. [3] [4] [5] For patients with unresectable tumors, available therapeutic options include mitotane (the only drug approved for the treatment of ACC), systemic cytotoxic chemotherapy, and radiation therapy. While several retrospective studies suggest an impact of mitotane on overall survival (OS), 2,6-9 the observed magnitude of benefit remains unclear. A randomized trial in ACC has recently shown a significantly longer progression-free survival (PFS) with a combination of mitotane/etoposide, doxorubicin and cisplatin as first-line therapy versus mitotane/streptozocin combination, although the difference in OS did not reach significance. 10 Insulin-like growth factor-2 (IGF-2) overexpression is the most common molecular event in
ACC and is present in some 90% of tumors. [11] [12] [13] IGF-2 signals through the insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) to initiate a downstream signaling cascade that drives proliferation, migration, and metastasis of ACC and other cancers. 14 Preclinical and phase 1 studies using a variety of IGF-1R inhibitors have shown promising results, suggesting that antagonizing IGF-1R signaling may be a valuable approach in treating ACC. [15] [16] [17] Linsitinib (OSI-906) is a potent, oral, small molecule inhibitor of both IGF-1R and IR which has shown preliminary evidence of antitumor activity in a variety of solid tumors, with an acceptable tolerability profile. [18] [19] [20] Notably, in a dose-finding, phase 1 study, linsitinib resulted in partial responses in two of 15 patients with ACC (79 total study patients). 19 We report here the results of an international phase 3 study evaluating linsitinib in patients with advanced ACC who received at least one but not more than two prior drug regimens.
Methods

Study design and endpoints
This randomized, double-blind, placebo-controlled, phase 3 trial was conducted at clinical sites in nine countries: Australia (1), Canada (3), Germany (3), France (6), Italy (2), the Netherlands (3), Poland (1), the United Kingdom (2), and the United States (14) . No other anticancer therapies, including mitotane, or investigational drugs were permitted during the study. Prior use of oral antihyperglycemic agents was allowed if the dose was stable ≥4 weeks prior to randomization. All patients received best supportive care for management of symptoms and toxicity and provided written informed consent.
Treatment and randomization
Patients were randomized in a 2:1 ratio to either linsitinib or matching placebo, and were stratified according to the following parameters: prior systemic cytotoxic therapy for ACC (yes or no), ECOG PS (0-1 or 2), and use of ≥1 non-insulinotropic oral antihyperglycemic therapy at randomization (yes or no). Unique patient identification numbers were generated via a web-based, centralized randomization system and used to link each patient to the appropriate treatment group.
The identity of the study agent was concealed and patients, investigators, site staff, and sponsor team were blinded to treatment. All patients received study agent (150 mg) twice daily (recommended phase 2 dose of lisitinib 19 ) with food by continuous dosing schedule for 21-day treatment periods. Treatment was discontinued for disease progression or for unacceptable toxicity. Study agent was withheld for drug-related ≥grade 3 toxicity; at resolution of toxicity to grade 1, study agent was reintroduced at 100 mg twice daily (75 mg twice daily for second AE recurrence). The study agent could be reduced to 100 mg twice daily at the discretion of the investigator for clinically significant grade 1/2 drug-related toxicities or any grade unrelated toxicities, but could not be re-escalated.
Assessments
A physical examination, including ECOG PS assessment and vital signs, was performed at screening, pre-dose on day 1 of every 21-day treatment period, and post-treatment. To assess efficacy, tumor response and progression were evaluated by chest, abdomen, and pelvic CT scan (magnetic resonance imaging for contraindications) after every 2 treatment 
Statistical analysis
Efficacy was assessed in the intent-to-treat population (all randomized patients). Safety was assessed in the safety population, which included all patients who received ≥1 dose of study drug and for whom any data were reported after first dose. The pharmacokinetic population included all patients who received active drug and for whom there was ≥1 measurable concentration and the pharmacodynamic population included patients who received active drug and for whom there were sufficient data for analysis. OS and PFS were estimated using the Kaplan-Meier method and compared using the unstratified log-rank test. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated using a and an assumption of 80% power to detect a HR 0.58 for OS (median OS 274 vs 474 days), 112 deaths were required to be observed from 135 enrolled patients. The interim analysis of OS was to be performed when 67 deaths were observed, by an independent statistician not affiliated with the sponsor.
This study is registered with ClinicalTrials.gov, number NCT00924989.
Role of the funding source
As the sponsor of the study, Astellas financially supported the study, provided linsitinib and placebo free of charge, and was responsible for data collection and analysis. Astellas and a Scientific Steering Committee were involved in the study design. The authors had full access to all study data and prepared this report with Astellas, who had the right to review the report before publication. The authors had final responsibility for the decision to submit for publication.
Results
Between December 2, 2009 and July 11, 2011, 139 patients were randomized (figure 1).
One patient in the placebo group did not receive any treatment due to primary investigator-assessed general deterioration, and was excluded from the safety population.
The trial was unblinded in March 2012 based on recommendation of the data monitoring committee. At that point, 6 patients were on study treatment, 2 of whom were receiving placebo. Patients were informed of the risk/benefit of continuing treatment. The 2 patients receiving placebo were not permitted to remain on the study. Overall, baseline demographic and disease characteristics were similar between the two treatment groups (table 1) . Approximately 91% of patients had been previously treated with surgery, and 31% with radiotherapy. All patients received prior anticancer drug regimens including mitotane (table 1) .
At database lock, median OS was 323 days (95% CI 256-507) in the linsitinib group and 356 days (249-556) in the placebo group (HR 0·94; 95% CI 0·61-1·44; p=0·771; figure 2). Based on independent radiologist review, median PFS was 44 days (95% CI 43-61) in the linsitinib group and 46 days (95% CI 43-64) in the placebo group (HR 0·83, 95% CI 0·56-1·21; p=0·303; figure 3), giving 17% risk reduction for the entire study population. Complete response was not achieved in any patient; PR was documented in 3 patients in the linsitinib 13 group (3·3%), but in none of the placebo group. DCR rate (CR+PR+SD) at 6 weeks was 32·2%
(95% CI 22·8-42·9) in the linsitinib group vs 34·7% (21·7-49·6) in the placebo group, while it was 15·6% vs 8·2% at 12 weeks and 6·7% vs 0% at 24 weeks. The best change in target lesion size for patients in both arms is illustrated in a waterfall plot (figure 4).
Of the 4 patients who continued on linsitinib after unblinding, 2 patients with a PR as a best response have rolled over to a separate linsitinib study in June and July 2014 following 45
and 38 months on study drug. Another patient with PR as the best response discontinued study drug at 37 months due to an unrelated AE. Interestingly, all 3 responders had relatively low-grade ACC with Ki67 of 3, 10, and 20%. The fourth patient had SD as a best response, and was on study drug for 23 months.
Predefined subgroup analyses of OS and PFS by sex, age, ECOG PS at baseline, smoking history, use of prior systemic and cytotoxic chemotherapy, and use of non-insulinotropic antihyperglycemic drug provided no evidence of differential treatment effect for linsitinib versus placebo.
Mean and median overall drug exposure time was similar between the two groups, with a mean of 100 days and a median of 44·0 days for linsitinib, and a mean of 84·9 days and a median of 47·0 days for placebo. Disease progression was the most common reason for treatment discontinuation for both groups (76·7% for linsitinib and 83·7% for placebo), followed by AEs (13·3% and 4·1%), other medico-ethical reasons (3·3% and 8·2%), and patient-initiated withdrawal (2·2% and 4·1%). 
Discussion
ACC is a rare and frequently fatal cancer, with limited therapeutic options. 2, 3, 9 In this phase 3 study we sought to confirm preliminary evidence of antitumor activity shown by linsitinib in patients with ACC. 19 The results of the present study failed to show a statistically determining the sensitivity of tumors to this agent. 22 No particular signature for response to IGF-1R inhibition has yet been identified in ACC. A possible negative impact on response to platinum-based therapies has been found for high expression levels of the DNA repair gene excision repair complementation group 1 (ERCC1), 23 and high ribonucleotide reductase large subunit (RRM1) gene expression had some association with poor efficacy of adjuvant mitotane therapy. 24 As expected, the pharmacokinetic profile of linsitinib was similar to that observed in a dosedetermining phase 1 study, with rapid absorption after oral dose and accumulation following continuous twice-daily dosing. 19 In the present study, high variability in PK was observed in treatment period 2, perhaps due to several factors including but not limited to age, weight, and concomitant medications. 
